The Medicare Part B Demo May be Dead, but Drug Pricing Concerns Still Linger

Mintz - Health Care Viewpoints

The Centers for Medicare & Medicaid Services (CMS) has withdrawn its controversial rule implementing the Medicare Part B payment demonstration. The agency stated that after consideration of the comments, it will not move forward with the demo.

The demonstration was intended to test new reimbursement methods for Medicare Part B drugs and to promote value-based and cost-effective drug purchasing.  Despite its intentions, major patient, pharmaceutical, and physician groups criticized the scope of the rule and the speed in which CMS was implementing it.  Many worried it would restrict or limit access to certain drugs.  It also drew sharp criticism from several members of Congress, including President-elect’s nominee for the Secretary of Health and Human Services, Rep. Tom Price.

This withdraw should not come as a shock to many in the industry.  We previously predicted that the likelihood of the Part B payment demonstration coming to fruition was extremely low.  Nonetheless, while the Medicare Part B payment demonstration may have been withdrawn, the concerns about drug pricing remain.  Data from CMS shows overall health spending grew by 5.8 percent in 2015, due in large part to increased prescription drug spending.  In an exclusive interview with Politico Pro, the Acting Administrator of CMS, Andy Slavitt predicted that this would be one of the top issues of his successor if prescription drug costs continue to grow.

[View source.]

Written by:

Mintz - Health Care Viewpoints

Mintz - Health Care Viewpoints on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.